Financial Report: Cangene

Cangene
 
3Q Revenues: $40.2 million (+46%)

3Q Earnings: $3.8 million (loss of $4.6 million 3Q13)

YTD Revenues: $102.6 million (+24%)

YTD Earnings: $5.0 million (loss of $12.9 million YTD12)

Comments: The increase included an $18.6-million holdback payment from the U.S. government that was triggered by Cangene achieving licensure of botulism antitoxin (BAT). The revenue increase was partially offset by lower HepaGam B sales in the U.S. Also, the prior-year quarter included product and plasma deliveries under the BAT contract and $1.8 million in revenue from non-specialty plasma sales (following the sale of its plasma centers in October 2012, Cangene no longer collects and sells non-specialty plasma). In the third quarter, combined WinRho SDF revenues were flat.